Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1358762/000156459017023433/reta-10q_20170930.htm
SEC Filings
RETA Annual Reports
RETA Quarterly Reports
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
RETA Corporate News
Earnings Release
Financial Exhibit
Regulated Disclosure August 2022
Event for Officers
Financial Exhibit
Regulated Disclosure July 2022
Event for Officers
Vote of Security Holders June 2022
Earnings Release
Financial Exhibit
Regulated Disclosure May 2022
Event for Officers March 2022
Earnings Release
Financial Exhibit
Regulated Disclosure February 2022
Event for Officers February 2022
Earnings Release
Financial Exhibit
Regulated Disclosure November 2021
Event for Officers October 2021
New Agreement August 2021
Earnings Release
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
August 2022
Event for Officers
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
July 2022
Event for Officers
Vote of Security Holders
Vote of Security Holders
June 2022
Earnings Release
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
May 2022
Event for Officers
March 2022
Earnings Release
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
February 2022
Event for Officers
February 2022
Earnings Release
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
November 2021
Event for Officers
October 2021
New Agreement
August 2021
Last10K.com | 10-Q Quarterly Report Mon Nov 13 2017
Exhibit 99.1
Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results
IRVING, Texas, November 13, 2017
– Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2017, and provided an update on the Company's business and product development programs.Financial Highlights
The Company incurred operating expenses of $24.6 million for the quarter ended September 30, 2017, with research and development accounting for $18.3 million. This compares to operating expenses of $13.5 million for the same period of the year prior, when research and development accounted for $9.3 million. A net loss of $12.3 million was reported by the Company for the quarter ended September 30, 2017, equating to a loss of $0.50 per share, compared to net loss of $0.9 million or $0.04 per share in the same period of the year prior.
The Company incurred operating expenses of $68.5 million for the nine months ended September 30, 2017, with research and development accounting for $50.8 million. This compares to operating expenses of $40.0 million for the same period of the year prior, when research and development accounted for $27.7 million. A net loss of $31.0 million was reported by the Company for the nine month period ended September 30, 2017, equating to a loss of $1.34 per share, compared to net loss of $2.1 million or $0.11 per share in the same period of the year prior.
Corporate Highlights
As of September 30, 2017, the Company had $154.6 million in cash and cash equivalents.
On November 3, 2017, the Company amended its loan agreement (Amended Loan Agreement) with Oxford Finance LLC and Silicon Valley Bank to increase its Term B Loan amount from $15.0 million to either $20.0 million or $25 million. The Company may, at its sole discretion, borrow $20 million under Term B Loan. An additional $5 million will be available under the Term B Loan for a total of $25 million upon the achievement of one of two milestones. The Company may borrow the Term B Loan by the earlier of 90 days after the achievement of a milestone or June 29, 2018. If the Term B Loan is drawn, the interest-only payment period would be extended by six months.
The following information was filed by Reata Pharmaceuticals Inc (RETA) on Monday, November 13, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Reata Pharmaceuticals Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Reata Pharmaceuticals Inc.
Assess how Reata Pharmaceuticals Inc's management team is paid from their Annual Proxy
Reata Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Expense Highlight
Net cash used in operating activities was $58.5 million for the nine months ended September 30, 2017, consisting primarily of net loss of $31.0 million adjusted for non-cash items including stock-based compensation expense of $4.7 million, depreciation and amortization expense of $0.4 million, and a net decrease in operating assets and liabilities of $32.6 million.
-
Financial - Expense Highlight
We have also incurred increased expenses associated with being a public company, including exchange listing and SEC requirements, director and officer insurance premiums, legal, audit, and tax fees, regulatory compliance programs, and investor relations costs.
-
Revenue - Product Highlight
To date, we have raised gross cash proceeds of $476.6 million through the sale of convertible preferred stock and received $750 million from payments under license and collaboration agreements, $169.8 million in net proceeds from our initial public offering and follow-on offering of our Class A common stock, and $19.7 million in net proceeds from our Loan Agreement in March 2017.
-
Other - Other Highlight
Therefore, by addressing a novel pathway in PAH, we believe that bardoxolone methyl may provide additional benefits beyond current PAH therapies, including increased functional capacity, potential effects beyond functional improvements and potential as a combination therapy with other current therapies.
-
Financial - Earnings Highlight
Our failure to become and remain profitable could depress the market price of our Class A common stock and could impair our ability to raise capital, expand our business, diversify our product offerings, or continue our operations.
-
Other - Other
We anticipate that we will...Read more
-
Other - Other
Because bardoxolone methyl was active...Read more
-
Financial - Expense
We believe our existing cash...Read more
-
Other - Other
We paid an amendment fee...Read more
-
Financial - Shares
On August 1, 2017, we...Read more
-
Revenue - Product
License and milestone revenue increased...Read more
-
Other - Other
We have selected and are...Read more
-
Other - Other
The financial terms of these...Read more
-
Other - Other
Accordingly, treatments may receive marketing...Read more
-
Financial - Expense
The increase was primarily due...Read more
-
Revenue - Product
On July 10, 2017, we...Read more
-
Financial - Expense
General and administrative expenses increased...Read more
-
Financial - Expense
General and administrative expenses increased...Read more
-
Financial - Expense
Our other research and development...Read more
-
Financial - Expense
Costs for certain development activities...Read more
-
Revenue - Product
The decrease in deferred revenue...Read more
-
Other - Other
Net cash provided by financing...Read more
-
Financial - Expense
Research and development expenses increased...Read more
-
Financial - Expense
Research and development expenses increased...Read more
-
Other - Other
Patients with MM present a...Read more
-
Other - Other
Muscle spasms were generally transient...Read more
-
Financial - Expense
the costs of development efforts...Read more
-
Other - Other
If beneficial effects are demonstrated...Read more
-
Financial - Expense
Interest expense increased by $0.5...Read more
-
Financial - Expense
Interest expense increased by $1.0...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Unaudited Consolidated Statements Of Cash Flows
Unaudited Consolidated Statements Of Operations
Description Of Business
Description Of Business - Additional Information (details)
Income Taxes
Net Loss Per Share
Net Loss Per Share (tables)
Net Loss Per Share - Additional Information (details)
Net Loss Per Share - Computation Of Basic And Diluted Net Loss Per Share (details)
Related-party Transactions
Related-party Transactions - Additional Information (details)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (details)
Stock-based Compensation - Summary Of Stock Based Compensation Expense (details)
Stock-based Compensation - Summary Of Stock Option Activity (details)
Subsequent Events
Subsequent Events - Additional Information (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies - Additional Information (details)
Term Loan
Term Loan (tables)
Term Loan - Additional Information (details)
Term Loan - Schedule Of Future Principal Payments For Term A Loan (details)
Material Contracts, Statements, Certifications & more
Reata Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits
Ticker: RETA
CIK: 1358762
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-17-023433
Submitted to the SEC: Mon Nov 13 2017 7:51:16 AM EST
Accepted by the SEC: Mon Nov 13 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/reta/0001564590-17-023433.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...